These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 24450506)

  • 1. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.
    Barriere SL
    Future Microbiol; 2014; 9(3):281-9. PubMed ID: 24450506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
    Sandrock CE; Shorr AF
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S79-86. PubMed ID: 26316561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.
    Lacy MK; Stryjewski ME; Wang W; Hardin TC; Nogid B; Luke DR; Shorr AF; Corey GR; Barriere SL
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S87-93. PubMed ID: 26316562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.
    Nannini EC; Corey GR; Stryjewski ME
    Expert Rev Anti Infect Ther; 2012 Aug; 10(8):847-54. PubMed ID: 23030322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections.
    Barriere SL
    Future Microbiol; 2010 Dec; 5(12):1765-73. PubMed ID: 21080861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure.
    Torres A; Rubinstein E; Corey GR; Stryjewski ME; Barriere SL
    J Antimicrob Chemother; 2014 Apr; 69(4):1119-26. PubMed ID: 24398339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical positioning of telavancin in Europe.
    Masterton R; Cornaglia G; Courvalin P; Lode HM; Rello J; Torres A
    Int J Antimicrob Agents; 2015 Mar; 45(3):213-20. PubMed ID: 25600892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus.
    McKinnell JA; Corman S; Patel D; Leung GH; Gordon LM; Lodise TP
    Clin Ther; 2018 Mar; 40(3):406-414.e2. PubMed ID: 29454592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telavancin (Vibativ). A vancomycin derivative, no more effective but more toxic.
    Prescrire Int; 2015 Nov; 24(165):257-9. PubMed ID: 26688891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.
    Liapikou A; Dimakou K; Toumbis M
    Ther Adv Respir Dis; 2016 Aug; 10(4):368-78. PubMed ID: 27340253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.
    Rubinstein E; Corey GR; Stryjewski ME; Kanafani ZA
    Expert Opin Pharmacother; 2011 Dec; 12(17):2737-50. PubMed ID: 22077833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
    Rubinstein E; Lalani T; Corey GR; Kanafani ZA; Nannini EC; Rocha MG; Rahav G; Niederman MS; Kollef MH; Shorr AF; Lee PC; Lentnek AL; Luna CM; Fagon JY; Torres A; Kitt MM; Genter FC; Barriere SL; Friedland HD; Stryjewski ME;
    Clin Infect Dis; 2011 Jan; 52(1):31-40. PubMed ID: 21148517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia.
    Stryjewski ME; Barriere SL; Rubinstein E; Genter FC; Lentnek AL; Magana-Aquino M; Luna CM; Niederman MS; Torres A; Corey GR
    Int J Antimicrob Agents; 2013 Oct; 42(4):367-9. PubMed ID: 23891527
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.
    Adamantia L; Antoni T
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):803-12. PubMed ID: 27158752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials.
    Nogid B; Lacy MK; Jacobs M; Bruss J; Dwyer J
    Pharmacotherapy; 2018 Oct; 38(10):990-998. PubMed ID: 30003567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
    Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
    Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telavancin: a review of its use in patients with nosocomial pneumonia.
    Scott LJ
    Drugs; 2013 Nov; 73(16):1829-39. PubMed ID: 24190596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.
    Hegde SS; Janc JW
    Expert Rev Anti Infect Ther; 2014 Dec; 12(12):1463-75. PubMed ID: 25382700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of telavancin in the treatment of MRSA infections in hospital.
    Bassetti M; Mikulska M; Righi E; Nicolini L; Viscoli C
    Expert Opin Investig Drugs; 2009 Apr; 18(4):521-9. PubMed ID: 19335280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
    Stein GE; Wells EM
    Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.